Stockscreener 앱 받기
1.0809
1.97%
0.0209
전일 마감가:
$1.06
열려 있는:
$1.05
하루 거래량:
42,434
Relative Volume:
0.57
시가총액:
$9.42M
수익:
$6.74M
순이익/손실:
$-14.74M
주가수익비율:
-0.4806
EPS:
-2.2491
순현금흐름:
$-18.31M
1주 성능:
-4.77%
1개월 성능:
-11.40%
6개월 성능:
-2.62%
1년 성능:
-25.97%
1일 변동 폭
$1.05
$1.0955
1주일 범위
$1.00
$1.14
52주 변동 폭
$0.95
$2.42
Evogene Ltd Stock (EVGN) Company Profile
EVGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.0809 | 9.24M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-08 | 개시 | ROTH Capital | Buy |
| 2021-07-29 | 개시 | Aegis Capital | Buy |
| 2020-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2013-12-16 | 개시 | Oppenheimer | Outperform |
Evogene Ltd 주식(EVGN)의 최신 뉴스
What drives Evogene Ltd stock priceEarnings Volatility Patterns & Low Cost Market Strategies - earlytimes.in
Will Evogene Ltd. stock keep outperforming rivalsEarnings Performance Report & Accurate Technical Buy Alerts - BỘ NỘI VỤ
Evogene (NASDAQ:EVGN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL (PR Newswire) - Aktiellt
Evogene shares climb 5% as cost reductions help deliver earnings beat - MSN
Evogene Ltd. Reports Strategic Shift and Financial Results - MSN
Evogene Ltd. Earnings Call: Strategic Shifts and Optimism - The Globe and Mail
Is Evogene Ltd. stock cheap compared to fundamentals - newser.com
Evogene Ltd. (NASDAQ:EVGN) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Evogene Ltd. stock hit record highs again2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Is Evogene Ltd. stock oversold or undervalued2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Evogene: Q3 Earnings Snapshot - Stamford Advocate
Evogene earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Evogene Q3 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Evogene(EVGN.US) Q3 2025 Earnings Conference - 富途牛牛
Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com India
Evogene shares rise 5% as cost-cutting measures drive earnings beat - Investing.com Nigeria
Evogene Reports Third Quarter 2025 Financial Results - The AI Journal
Evogene Reports Q3 2025 Financial Results Amid Strategic Shift - TipRanks
Israeli biotech firm Evogene's Q3 revenue misses estimates due to reduced seed sales - TradingView
Evogene shares rise 5% as cost-cutting measures drive earnings beat By Investing.com - Investing.com South Africa
Evogene : Q3 2025 Consolidated Financial Statements - MarketScreener
[6-K] Evogene Ltd. Current Report (Foreign Issuer) | EVGN SEC FilingForm 6-K - Stock Titan
Will Evogene Ltd. stock outperform international peers2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Evogene Ltd. stock maintain growth storyMarket Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
[EFFECT] Evogene Ltd. SEC Filing - Stock Titan
Is Evogene Ltd. stock a buy for dividend growthJuly 2025 PostEarnings & Short-Term Swing Trade Alerts - newser.com
How strong is Evogene Ltd. stock revenue growthCEO Change & Free Community Consensus Stock Picks - newser.com
Evogene Ltd. stock prediction for this weekGDP Growth & Weekly Top Gainers Trade List - newser.com
What technical models suggest about Evogene Ltd.’s comeback2025 Performance Recap & Reliable Intraday Trade Plans - newser.com
What's Next: Evogene's Earnings Preview - Benzinga
Evogene Ltd (EVGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):